Controlled therapeutic trial with the combination rifampicin-isoniazid given for six months to previously untreated patients with pulmonary tuberculosis.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D001118:Argentina; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004977:Ethambutol / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012293:Rifampin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D013183:Sputum / Q000382:microbiology; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D004338:Drug Combinations; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin